Drug Trial Radar · NCT01821391
Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses
Last checked: Nov 20, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Jul 2013
Primary completion
Jan 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to be conducted as a multi-centre, randomized, investigator-blinded, active and vehicle-controlled, intra-individual (split-face/scalp) non-inferiority (regarding efficacy) and superiority (regarding pain) study. The primary purpose of this study is to demonstrate the non-inferiority of NDL-PDT compared to c-PDT in terms of lesion complete response rate.
Conditions
- Actinic Keratoses
Interventions
NDL-PDTDrug
Metvix natural daylight photodynamic therapy
c-PDTDrug
Metvix conventional photodynamic therapy
placebo c-PDTDrug
Metvix placebo conventional photodynamic therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage (%) Change From Baseline in Total Lesion Complete Response at Week 12 in Group 1Time frame: Baseline, Week 12
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
Investigative site
Montpellier, France
Investigational site
Nantes, France
Investigational site
Nice, France
Investigational site
Paris, France
Investigative site
Rennes, France
Investigational site
Aachen, Germany
Investigational site
Berlin, Germany
Investigational site
Münster, Germany
Investigational site
Recklinghausen, Germany
Investigational site
Assen, Netherlands
Investigational site
Maastricht, Netherlands
Investigational site
Nijmegen, Netherlands
Investigational site
Huesca, Spain
Investigational site
Madrid, Spain
Investigative site
Pamplona, Spain
Investigational site
Valencia, Spain
Investigational site
Karlskoga, Sweden
Investigational site
Norrköping, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.